BCM
FATE icon

Bronte Capital Management’s Fate Therapeutics FATE Stock Holding History

Bronte Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.4K Hold
22,853
– – ﹤0.01% 48
2025
Q4 		$22.5K Buy
+22,853
New +$27.4K ﹤0.01% 41

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bronte Capital Management's FATE Position: Q1 2026 in Review

Bronte Capital Management held its Fate Therapeutics (FATE) position steady in Q1 2026 at 22,853 shares worth $27.4K. The position accounts for ﹤0.01% of the portfolio, ranked #48.

Bronte Capital Management first reported a position in FATE in Q4 2025 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Bronte Capital Management held 22,853 shares of Fate Therapeutics worth $27.4K as of Q1 2026.
  • Bronte Capital Management left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Bronte Capital Management's portfolio in Q1 2026, its #48 holding.
  • Bronte Capital Management first reported a position in Fate Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Bronte Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.